背景:研究表明,血清asprosin和irisin与2型糖尿病(T2DM)和肥胖有关。这项研究评估了循环水平的asprosin和irisin及其与人体测量和代谢参数的关系。尤其是2型糖尿病合并腹型肥胖(AO)患者的内脏脂肪面积(VFA)。
方法:在本病例对照研究中,131例T2DM患者根据其VFA分为AO组(n=68)和非AO组(n=63)。测量并比较两组之间的人体测量和代谢参数以及血清中的asprosin和irisin水平。
结果:与NAO组相比,AO组有显著较高的血清冬氨酸和irisin浓度(3.67±1.76ng/mLvs.2.85±0.90ng/mL,p=0.001;154.62±61.87pg/mL与130.54±34.89pg/mL,分别为p=0.008)和更大的VFA(p<0.001)。AO组的血清丙肾上腺素与体重呈正相关,腰围(WC),hipline,身体质量指数,空腹血糖(FBG),糖化血红蛋白(HbA1c),VFA,皮下脂肪面积,和腹部总脂肪面积(TAFA),AO组血清irisin浓度与WC呈正相关,腰臀比(WHR),VFA,TAFA与FBG呈负相关。Logistic逐步回归分析提示,FBG和VFA是与血清乙酰肝素呈正相关的独立因素,FBG是独立的,与血清irisin呈负相关,而VFA是独立的,与血清irisin呈正相关。
结论:伴有AO的T2DM患者血清中asprosin和irisin水平升高及其与其他代谢参数的相关性表明,两者都是治疗肥胖及其相关疾病的潜在治疗药物/靶点。
BACKGROUND: Studies have suggested that serum asprosin and irisin were involved in type 2 diabetes mellitus (T2DM) and obesity. This study evaluated circulating levels of asprosin and irisin and their associations with anthropometric and metabolic parameters, especially the visceral fat area (VFA) in T2DM patients with abdominal obesity (AO).
METHODS: In this
case-control study, 131 patients with T2DM were grouped into an AO group (n = 68) and a non-AO group (NAO) (n = 63) based on their VFA. Anthropometric and metabolic parameters as well as serum asprosin and irisin levels were measured and compared between the 2 groups.
RESULTS: Compared to the NAO group, the AO group had significantly higher serum asprosin and irisin concentrations (3.67 ± 1.76 ng/mL vs. 2.85 ± 0.90 ng/mL, p = 0.001; 154.62 ± 61.87 pg/mL vs. 130.54 ± 34.89 pg/mL, p = 0.008, respectively) and greater VFA (p < 0.001). Serum asprosin in the AO group was positively associated with weight, waist circumference (WC), hipline, body mass index, fasting blood glucose (FBG), glycated haemoglobin (HbA1c), VFA, subcutaneous fat area, and total abdominal fat area (TAFA), and the serum irisin concentration in the AO group was positively correlated with WC, waist-to-hip ratio (WHR), VFA, and TAFA and negatively correlated with FBG. Stepwise logistic regression analysis suggested that FBG and VFA were independent factors positively associated with serum asprosin, and that FBG was independently, negatively associated with serum irisin, while VFA was independently, positively associated with serum irisin.
CONCLUSIONS: Elevated serum asprosin and irisin levels in T2DM patients with AO and their correlations with other metabolic parameters suggest that both are potential therapeutic agents/targets in treating obesity and its related disorders.